Clinical trials: Human Papillomavirus Vaccines
Infections, Papillomavirus
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
The purpose of this Phase II study is to provide data regarding the safety and immunogenicity for a range of dose levels of MEDI-517 in women who are HPV-16/18 seronegative and negative for high-risk HPV DNA.
- Trial name
- NCT00693966
- Testing
- MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1), MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2), MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
CIN - Cervical Intraepithelial Neoplasia, HPV
Multiple Human Papillomavirus Infections in the Development of CIN
Multiple infections of high-risk genotypes of Human Papillomavirus (HR-HPV) in patients with abnormal cervical cytological or histological findings are detectable in a percentage ranging from 20% to 50% of cases.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, HPV, HPV Vaccines
- Trial name
- HPV dysplasia (NCT06862102)
- Testing
- HPV vaccine
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Human Papillomavirus (HPV)
Perception, Awareness, and Acceptance of Human Papillomavirus Disease and Vaccine Among Parents of Boys Aged 9 to 18 Years
The objectives of this study are: 1. to determine the degree of understanding and perceived risks for human papillomavirus (HPV) disease, to examine and assess attitudes for personal use of HPV vaccine and identify potential…
- Trial name
- NCT01197079
- Testing
- Survey
- Where
- 7 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
HPV Vaccine
Strengthening HPV Immunization Through EPI Leveraged Delivery
This is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9…
- Trial name
- SHIELD (NCT07377656)
- Testing
- HPV vaccine, Measles and rubella Vaccine
- Where
- Ghana
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Healthy Subject
Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men
This pilot trial studies how well a mobile health (mHealth) human papillomavirus (HPV) vaccine intervention works in increasing HPV vaccine coverage among young adult gay and bisexual men.
- Trial name
- NCT02835755
- Testing
- Educational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Warts, Verruca (Warts)
Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
This study will evaluate whether Gardasil-9, a vaccine normally used to prevent human papillomavirus (HPV) infection, may be effective for treating recurring warts that have not responded to standard treatments.
- Conditions
- Warts, Verruca (Warts), Verruca Vulgaris
- Trial name
- NCT07806617
- Testing
- 9-valent human papillomavirus vaccine, Sterile Saline
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Rush University Medical Center
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
This primary goal of this study is to assess whether patient whose parents watch a standardized digital video using the integrated digital approach during a routine office visit are more likely to accept a dose of HPV vaccine…
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02546752
- Testing
- THEO
- Where
- 5 sites in United States
- Volunteers
- 1,306 people
- Sponsor
- Regenstrief Institute, Inc.
Vaccination
The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study
The purpose of this study is to determine if women would find it acceptable to receive the HPV vaccine postpartum at the pediatrician's office at the time of their child's two-month well- child visit when offered during the third…
- Trial name
- NCT02602626
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HPV Infection, HPV-Related Cervical Carcinoma
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group.
- Trial name
- NCT04436133
- Testing
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9）
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Vaccination
HPV Vaccine Reminders - SEARCH II Study
This RCT will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic…
- Trial name
- NCT06161831
- Testing
- Text Message/automated phone reminder
- Where
- 2 sites in United States, Uganda
- Volunteers
- 396 people
- Sponsor
- Columbia University
Human Papilloma Virus Infection Type 16
Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus…
- Trial name
- URVIVE (NCT07407569)
- Testing
- Gardasil 9 (2 dose regimen)
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Universiteit Antwerpen
Papillomavirus Vaccines, HPV Vaccines
HPV Vaccine Integrated Service Implementation Research in Ethiopia
The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls in…
- Conditions
- Papillomavirus Vaccines, HPV Vaccines, HPV Vaccine Acceptability, HPV Vaccine Attitudes
- Trial name
- HPV-VISION (NCT06667323)
- Testing
- Integrated health service delivery for very young adolescent girls
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Population Services International
Human Papillomavirus Vaccines
Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9
This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9
- Trial name
- NCT03431246
- Testing
- Gardasil and Gardasil-9
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laval University
Human Papillomavirus
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination.
- Trial name
- NCT02236273
- Testing
- Conventional text message reminder, Enhanced text message reminders
- Where
- United States
- Volunteers
- 956 people
- Sponsor
- Columbia University
Recurrent Human Papillomavirus Type 16 Associated Cancer
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent…
- Trial name
- NCT05132803
- Testing
- HPV 16 TA-CIN
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Infections, Papillomavirus
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741)…
- Trial name
- NCT01418937
- Testing
- CervarixTM (GSK580299)
- Where
- 5 sites in Brazil
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus-Related Carcinoma
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women.
- Trial name
- NCT05985681
- Testing
- Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Healthy
Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand
This is a community intervention effectiveness study in female school students in Thailand. The study objectives are: 1. To demonstrate HPV vaccine effectiveness of Single Dose (SD) by a reduction in vaccine-type HPV prevalence…
- Trial name
- IVIHPV1 (NCT03747770)
- Testing
- Bivalent HPV vaccine CERVARIX®
- Where
- Thailand
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Healthy
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
The primary objective of this study is to describe the safety of 40 mg MEDI-517, with a control of aluminum hydroxide, when given to healthy adult women who have evidence of HPV-16 and/or HPV-18 DNA detected in cervical brushings.
- Trial name
- NCT00263744
- Testing
- MEDI 517, Aluminum hydroxide
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC